WO2012149465A3 - Modulation of cd36 expression - Google Patents

Modulation of cd36 expression Download PDF

Info

Publication number
WO2012149465A3
WO2012149465A3 PCT/US2012/035648 US2012035648W WO2012149465A3 WO 2012149465 A3 WO2012149465 A3 WO 2012149465A3 US 2012035648 W US2012035648 W US 2012035648W WO 2012149465 A3 WO2012149465 A3 WO 2012149465A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
methods
expression
modulation
Prior art date
Application number
PCT/US2012/035648
Other languages
French (fr)
Other versions
WO2012149465A2 (en
Inventor
Adam Mullick
Rosanne M. Crooke
Mark J. Graham
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Publication of WO2012149465A2 publication Critical patent/WO2012149465A2/en
Publication of WO2012149465A3 publication Critical patent/WO2012149465A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of a CD36 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or inflammatory disease, or a symptom thereof.
PCT/US2012/035648 2011-04-27 2012-04-27 Modulation of cd36 expression WO2012149465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479815P 2011-04-27 2011-04-27
US61/479,815 2011-04-27

Publications (2)

Publication Number Publication Date
WO2012149465A2 WO2012149465A2 (en) 2012-11-01
WO2012149465A3 true WO2012149465A3 (en) 2012-12-27

Family

ID=47073106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/035648 WO2012149465A2 (en) 2011-04-27 2012-04-27 Modulation of cd36 expression

Country Status (1)

Country Link
WO (1) WO2012149465A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322976B1 (en) * 1998-05-28 2001-11-27 Medical Research Council Compositions and methods of disease diagnosis and therapy
US20040077567A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
US20100105088A1 (en) * 2007-02-05 2010-04-29 Aarhus Universitet method for diagnosing atherosclerotic plaques by measurement of cd36

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322976B1 (en) * 1998-05-28 2001-11-27 Medical Research Council Compositions and methods of disease diagnosis and therapy
US20040077567A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression
US20100105088A1 (en) * 2007-02-05 2010-04-29 Aarhus Universitet method for diagnosing atherosclerotic plaques by measurement of cd36

Also Published As

Publication number Publication date
WO2012149465A2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2011085271A3 (en) Modulation of angiopoietin-like 3 expression
EP2603199A4 (en) Compositions and methods for treating cardiovascular disease
BR112013019732A2 (en) compositions and methods for treating cardiovascular disease
MY162715A (en) Modulation of apolipoprotein ciii (apociii) expression
EP2542060A4 (en) Compositions and methods for treating and/or preventing cardiovascular disease
EP2638159A4 (en) Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
WO2012012467A3 (en) Modulation of nuclear-retained rna
PL2779838T3 (en) Palatable pet foods and methods for improving the palatability of pet foods
EP2665726A4 (en) Compositions and methods for cardiovascular disease
SMT201400052B (en) Almond drinks and methods for their production
ZA201401438B (en) Methods for treating cardiovascular disorders
EA201070991A1 (en) COATED FOOD PRODUCTS AND METHODS FOR PRODUCING THEM
EP2688437B8 (en) Shoe having improved cushioning and propulsion
WO2013043817A8 (en) Antisense modulation of gcgr expression
BRPI1007600A2 (en) compositions and methods for treating cardiovascular disease
EP2523553A4 (en) Methods and compositions for treating bleeding disorders
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
BRPI1013361A2 (en) method to prevent and treat hypermeability.
WO2011112588A9 (en) Compositions and methods for treating inflammatory disorders
EP2544703A4 (en) Methods of treating vascular inflammatory disorders
EP2381920A4 (en) Methods and compositions for treating p.acnes
WO2011126842A3 (en) Targeting micrornas for the treatment of cardiac disorders
EP2616186A4 (en) Treatment of wood pieces
WO2010119424A3 (en) Composition for regulating the metabolism of lipids
HRP20170172T1 (en) Compositions pharmaceutiques fortement dosees en biotine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12777073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12777073

Country of ref document: EP

Kind code of ref document: A2